Locate Bio
Locate is based in MediCity and has developed a family of unique, thermally-activated, injectable scaffolds that solidify within the body and can be used to support tissue growth before degrading away.
Regenerative medicine
School of Pharmacy
Profile
The TAOSTM (Targeted, Orchestrated Signalling) technology is a world first in tissue repair and enables the precision focus of therapeutic signals from small molecule or biological actives at the site of repair. TAOSTM has many potential application sites across the body.
Pipeline technology includes RPMax, a thermo-reversible matrix, and IntraStem, a new delivery system for cells; technologies that can meet industry recognised needs to advance cell therapy markets such as transfection, genome editing and induced pluripotent stem cells.
News and press releases
Spin-out company launches that will revolutionise the power generation sector
- 10th April 2024 2:39 pm·
University spin-out named as a Bloomberg UK start-up to watch
- 25th October 2023 10:38 am·
Researchers develop new platform that could replace the use of animals in research
- 3rd August 2023 11:20 am·
Spin-out company launched to deliver gene therapy during bone repair surgery
- 13th June 2023 11:48 am·
Lewis Capaldi visits the Neupulse office to try out our wearable wrist device
- 30th January 2023 3:04 pm·
Neupulse raises £918k in a second round of funding
- 20th January 2023 1:05 pm·
Alevin wins Best Biotech Startup Company award at the prestigious OBN Awards 2022
- 19th November 2022 2:34 pm·
SurePulse and partners land £1.4m Innovate UK award
- 2nd November 2022 1:37 pm·
PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test
- 27th October 2022 11:40 am·
Nottingham trio share award for brain imaging innovation
- 27th October 2022 11:28 am·
Face and voice recognition technology set to transform diagnosis of perinatal depression
- 20th October 2022 4:01 pm·
Our mission is to provide next generation products, both as tools and treatments, that will allow regenerative medicine to realise its potential. Our proprietary TAOS and Intrastem technologies give Locate a unique opportunity to develop and enable the next generation of cellular and gene therapies.
Robin Quirk
Chief Operating Officer